Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Compass Therapeutics Inc. CMPX

Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is developing proprietary antibody-based therapeutics to treat multiple human diseases. Its pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. Its lead product candidate, CTX-009, is a bispecific... see more

Bullboard (NDAQ:CMPX)

View:
User Avatar Image
(147)
•••
  • coolfooldumbguyX
Post by coolfooldumbguyon Jan 28, 2025 11:34am

Buy buddy buy because it's taking off this morning.

This stock is a good buy and position for my portfolio.
User Avatar Image
(292)
•••
  • whytestocksX
Post by whytestockson Apr 10, 2024 3:00pm

Compass Therapeutics to Participate in the Stifel Targeted O

Breaking News: $CMPX Compass Therapeutics to Participate in the Stifel Targeted Oncology Days | BenzingaBOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities